Michael Joseph Tremblay Insider Profile
4 Followers
Michael Joseph Tremblay, Director at Knight Therapeutics, holds 2.00K shares in Knight Therapeutics (Ticker: KHTRF). Most recently, Michael Joseph Tremblay Sold 20,000 shares of Knight Therapeutics on Apr 15, 2026 for an estimated value of $151.60K.
Michael Joseph Tremblay has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
100.00%
A breakdown of Michael Joseph Tremblay's holdings
Insider Roles
Director
Roles that Michael Joseph Tremblay holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Michael Joseph Tremblay
Michael Joseph Tremblay's Trading History
List of latest transactions for each holding click on a transaction to see Michael Joseph Tremblay's performance on stock
You May Also Like
Michael Joseph Tremblay insider profile FAQ
What is the percentage of profitable transactions made by Michael Joseph Tremblay?
The percentage of profitable transactions made by Michael Joseph Tremblay is ―.
What is the average return per transaction made by Michael Joseph Tremblay?
The average return per transaction made by Michael Joseph Tremblay is ―.
What stocks does Michael Joseph Tremblay hold?
Michael Joseph Tremblay holds: KHTRF stocks.
What was Michael Joseph Tremblay’s latest transaction?
Michael Joseph Tremblay latest transaction was an Informative Sell of $151.60K.
What was Michael Joseph Tremblay's most profitable transaction?
Michael Joseph Tremblay’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Michael Joseph Tremblay's role in Knight Therapeutics?
Michael Joseph Tremblay's role in Knight Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.